Navigation Links
Caffeic acid inhibits colitis in a mouse model -- is a drug-metabolizing gene crucial?
Date:5/26/2009

This release is available in Chinese.

Researchers at Iowa State University have found that increased expression of a form of cytochrome P-450 (CYP4B1) is a key marker of inhibition of colitis in mice by caffeic acid, an anti-inflammatory antioxidant compound widely distributed in foods. The results, which appear in the June 2009 issue of Experimental Biology and Medicine, implicate CYP4B1, a form of cytochrome P450 previously found to be associated with resolution of allergic inflammation in another model. The normalization of CYP4B1 by caffeic acid treatment was associated with significant lessening of colitic damage, assessed by examining colon histopathology. In comparison with rutin, an anti-inflammatory flavonoid and hypoxoside extract, a botanical known as African potato previously shown to protect against colitis, all three compounds had anti-inflammatory effects, suppressing myeloperoxidase, IL-17 and iNOS and increasing IL-4, known factors associated with inflammation responses. But only caffeic acid protected against the dextran sulfate sodium induced colitis. Its novel mechanism related to CYP4B1 is being studied further. The research team, Zhong Ye, a graduate student in Toxicology, along with Microbiology graduate students Zhiping Liu and Abigail Henderson, Visiting Scientist Kwangwon Lee, Korea University, Dr. Michael Wannemuehler, Veterinary Microbiology, Dr. Jesse Hostetter, a veterinary pathologist, and Dr. Suzanne Hendrich, Toxicologist and Nutritionist, performed studies in 8 week old mice fed the various dietary components and then exposed to dextran sulfate sodium in a mildly irritating dose to induce colitis. Dr. Hendrich noted that "this study of caffeic acid will help us to advance studies of botanicals and plant foods with respect to their ability and mechanisms of inhibiting colitis, and perhaps colon cancer, because colitis increases risk for this disease".

In summary, normalization of expression of CYP4B1, a drug metabolizing enzyme possibly related to reversal of inflammatory damage was a hallmark of the efficacy of caffeic acid, a component found widely in plant foods in the human diet, to inhibit intestinal tissue damage in a mouse model commonly used to simulate colitis. Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "The article by Hendrich and colleagues may help in the future design of more effective treatments to prevent or diminish colitis".


'/>"/>

Contact: Dr. Suzanne Hendrich
shendric@iastate.edu
515-294-4272
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Herpes drug inhibits HIV in patients infected with both viruses
2. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
3. New genetic markers for ulcerative colitis identified, researchers report in Nature Genetics
4. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
5. A new mouse model provides insight into genetic neurological disorders
6. Diminuendo -- New mouse model for understanding cause of progressive hearing loss
7. Mouse model provides a new tool for investigators of human developmental disorder
8. CSHL team develops mouse models of leukemia that predict response to chemotherapy
9. Brain building: Study shows brain growth tied to cell division in mouse embryos
10. A worm-and-mouse tale: B cells deserve more respect
11. Salk researchers develop novel glioblastoma mouse model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
(Date:2/22/2017)... , Feb. 22, 2017 With the ... ABI Research identifies four technologies that innovative and ... secure significant share in the changing competitive landscape: ... passive authentication.   "Companies can no ... to security," says Dimitrios Pavlakis , Industry ...
(Date:2/14/2017)... 2017  Wake Forest Baptist Medical Center today announced Julie ... executive officer (CEO). Freischlag joins the medical center on ... , M.D., who last year announced that he would ... after leading it since 2008.   As ... Forest Baptist,s academic health system, which includes Wake Forest ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... Cousins Properties (NYSE: CUZ ) announced today that ... a 10-year, approximately 125,000 square-foot lease at Corporate Center, a ... Westshore submarket of Tampa, FL. ... Center for their new location in Tampa ... officer of Cousins Properties. "Amgen is a cutting-edge global company ...
(Date:3/27/2017)... ROCKVILLE, Md. , March 27, 2017 /PRNewswire/ ... $108.5 billion for 2016, according to a new ... patients, medical lab testing is performed to evaluate ... determine individual therapy, among other reasons.  The healthcare ... Services Market , provides an overview of ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... PMG ... Trial Collaborations (CTC) conference presented by The Conference Forum in Boston on April ... they collaborate to drive improved clinical trial outcomes and bring them closer to the ...
(Date:3/27/2017)... Israel , March 27, 2017 DarioHealth ... with mobile health and big data solutions, today announced ... party insurance coverage option for U.S. consumers who want ... DarioHealth has signed strategic alliance agreements with ... verify insurance coverage benefits, and if approved, will supply ...
Breaking Biology Technology: